Genmab A/s · OMXCOP:GMAB

Genmab A/s — Q3 2024 Earnings Presentation

13 slides from Genmab A/s's earnings presentation, Nov 6, 2024

  1. Slide 1: Quarter End Results

    Quarter End Results Period Ended September 30, 2024

  2. Slide 2: Forward looking statement

    Forward looking This presentation contains forward looking statements. The words “believe”, “expect”, development, uncertainties related to the outcome of clinical trials, slower than expected statement “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. ra

  3. Slide 3: Strategic Partnerships, Collaborations, and Licensing Agreements

    As part of the presentation of Genmab’s Results for the First Nine Months Strategic of 2024, we will discuss several products developed in collaboration with Partnerships, strategic partners or that are the result of product or technology licenses with other companies. This slide is an acknowledgeme

  4. Slide 4: Driving Towards Our 2030 Vision: Recent Company Events

    Driving Towards Our 2030 Vision: Recent Company Events • EPKINLY/TEPKINLY (epcoritamab) • Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) – Genmab is assuming sole responsibility for acasunlimab – Second European approval: relapsed or refractory follicular lymphoma – Phase 3 PD-L1 positive 2L+ NSCLC  Fi

  5. Slide 5: Genmab Commercialized Medicines Performance

    Genmab Commercialized Medicines Performance Net sales YTD * YoY** YTD YoY $203M - $92M +43% The CORE Therapy across B-cell Malignancies Clear answer in 2L+ Cervical Cancer • US: EPKINLY is the first-and-only BsAb approved for • 12 consecutive quarters of demand growth, driven by both 3L+ DLBCL and 3

  6. Slide 6: First Nine Months of 2024: Driving Towards Our 2030 Vision

    First Nine Months of 2024: Driving Towards Our 2030 Vision EPKINLY/TEPKINLY Regulatory Approvals & Launches, ProfoundBio Acquisition 37% increase in recurring revenues Focused Investment: maximizing the potential of our Phase 3 programs, Epkinly, Rina-S and acasunlimab Team and capabilities in place

  7. Slide 7: Royalties and Net Product Sales Drive 29% YoY Total Revenue Growth

    Royalties and Net Product Sales & Collaboration Revenue* Drive 29% YoY Total Revenue Growth Revenue, DKK Millions +29% 15,085 1,182 37% Recurring Revenue growth from Royalties 1,536 and Net Product Sales & Collaboration Revenue 11,715 1,586  Higher DARZALEX Royalties from >19% YoY Net 407 Sales gro

  8. Slide 8: Focused Investments in Pipeline and Capabilities

    Focused Investments in Pipeline and Capabilities Operating Expenses, DKK Millions 9,894 178 269 Advancing Portfolio 1,402  Expanding mid/late-stage development 8,045 programs – EPKINLY, acasunlimab and Rina-S SG&A growth moderating which reflects our focus on driving efficiency Securing EPKINLY lau

  9. Slide 9: Condensed Income Statement: Nine Months Ended September 30

    Condensed Income Statement: Nine Months Ended September 30 2024 2023 2024 2023 DKKM Change USDM * Total Revenue 15,085 11,715 3,370 2,265 1,759 Royalties 12,367 9,722 2,645 1,857 1,460 Net Product Sales/Collaboration Revenue** 1,536 407 1,129 231 61 Milestone and Reimbursement 1,182 1,586 (404) 177

  10. Slide 10: 2024 Guidance Update: Driving Growth Through Higher Revenue and OPEX Prioritization

    2024 Guidance Update: Driving Growth Through Higher Revenue and OPEX Prioritization YoY Growth* Previous Previous Revenue growth of 30% YoY vs previous DKK Billions Guidance Guidance Guidance Guidance guidance of 28%* driven by:  DARZALEX royalties of ~DKK 13.7B to Revenue 20.5 - 21.7 21.1 - 21.7 2

  11. Slide 11: Summary

    Summary  Clear path to reach our 2030 Vision  Growing recurring revenue streams and significant underlying profitability  Focused and disciplined investment approach  Significant growth opportunities supported by our capital allocation strategy © Genmab 2024 11 For Investor audience only. Not fo

  12. Slide 12: 2024 Priorities: Further Advancing Our Differentiated Product Pipeline Towards The Market

    Further Advancing Our Differentiated 2024 Priorities: Product Pipeline Towards The Market Invest in Our People, Culture & Society Further scale organization aligned with differentiated Bring Our Own Medicines to Patients & Build World-class Differentiated antibody product portfolio Expand Our Market

  13. Slide 13: Q&A Upcoming Investor Events

    Q&A Upcoming Investor Events Jefferies Global Healthcare Conference, November 19 - 21, 2024 Citi Healthcare Conference, December 3 – 5, 2024 R&D Update and ASH Data Review, December 11, 2024 JP Morgan Healthcare Conference, January 13-16, 2025 For Investor audience only. Not for public information o

Genmab — Q3 2024 Earnings Presentation on 6ix